Original article

Association of inflammatory cytokines with mortality in peritoneal dialysis patients

¹ Graduate Institute of Clinical Medical Science, China Medical University College of Medicine, Taichung 404, Taiwan
² Department of Internal Medicine, China Medical University College of Medicine, Taichung 404, Taiwan
³ Division of Nephrology, China Medical University Hospital, Taichung 404, Taiwan
⁴ Division of Nephrology, Taichung Veteran General Hospital, Taichung 407, Taiwan
⁵ Department of Medical Research, China Medical University Hospital, Taichung 404, Taiwan
⁶ Division of Immunology and Rheumatology, China Medical University Hospital, Taichung 404, Taiwan
⁷ Graduate Institute of Integrated Medicine, China Medical University, Taichung 404, Taiwan

^* Corresponding author. No. 2, Yu-Der Road, Division of Nephrology, China Medical University Hospital, Taichung 404, Taiwan. E-mail address: oasisbestonly@yahoo.com.tw (S.-Y. Lin)

Received: 12 September 2016
Accepted: 29 September 2016

Abstract

Aims: Previous study on association between pro-inflammatory cytokines and mortality in PD population is limited. We aimed to investigate here.

Methods: Total 50 patients who underwent incident PD were enrolled in this study. We measured the titers of pro-inflammatory cytokines Interleukin-18(IL-18), Interleukin-6 (IL-6), and Interleukin-1ß (IL-1ß). Study outcomes were all-cause mortality, cardiovascular-related mortality, and infection-caused mortality. Cox-regression model was used.

Results: In this 7 year prospective study, IL-18 ≥ 804.3pg/ml, IL-6 ≥ 3.92 pg/ml, IL-1ß ≥ 0.86pg/ml, age ≥ 50 years-old, and existence of diabetes could be used as individual significant predictors for mortality in PD patients. Higher titers of IL-6 were associated with lower averaging albumin levels within 1^st year of PD. Increasing numbers of these risk markers of mortality was associated with decreasing survival advantages (P = 0.001).

Conclusion: Age ≥ 50 years-old, diabetes, and inflammatory cytokines profiles at the start of PD therapy could predict for 7-year mortality in PD population.